BidaskClub lowered shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) from a hold rating to a sell rating in a report published on Thursday morning.

A number of other analysts also recently commented on the company. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a hold rating to a sell rating in a research note on Tuesday, May 2nd. Mizuho dropped their price objective on Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a neutral rating on the stock in a research note on Wednesday, May 31st. Cowen and Company reissued an outperform rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, May 10th. Janney Montgomery Scott raised Jazz Pharmaceuticals PLC from a neutral rating to a buy rating and boosted their price objective for the stock from $138.00 to $175.00 in a research note on Thursday, April 6th. Finally, Deutsche Bank AG set a $176.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a buy rating in a research note on Thursday, April 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals PLC has an average rating of Buy and an average target price of $182.56.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded up 0.77% on Thursday, hitting $155.60. The stock had a trading volume of 366,705 shares. The firm has a market cap of $9.34 billion, a P/E ratio of 23.51 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The company’s 50-day moving average price is $155.48 and its 200 day moving average price is $145.64.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing the Zacks’ consensus estimate of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The firm had revenue of $376.10 million during the quarter, compared to the consensus estimate of $376.58 million. During the same period in the prior year, the firm posted $2.26 EPS. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $11.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/06/jazz-pharmaceuticals-plc-nasdaqjazz-downgraded-by-bidaskclub-to-sell.html.

In related news, EVP Suzanne Sawochka Hooper sold 4,580 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $160.00, for a total transaction of $732,800.00. Following the transaction, the executive vice president now directly owns 32,322 shares of the company’s stock, valued at $5,171,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 30,000 shares of the company’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $153.47, for a total value of $4,604,100.00. Following the transaction, the chief executive officer now directly owns 296,418 shares in the company, valued at $45,491,270.46. The disclosure for this sale can be found here. Insiders have sold 43,100 shares of company stock worth $6,645,820 over the last three months. 4.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals PLC by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 147,511 shares of the specialty pharmaceutical company’s stock valued at $16,082,000 after buying an additional 408 shares during the last quarter. Teachers Advisors LLC raised its position in Jazz Pharmaceuticals PLC by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 151,056 shares of the specialty pharmaceutical company’s stock valued at $16,470,000 after buying an additional 13,119 shares during the last quarter. Bridges Investment Management Inc. acquired a new position in Jazz Pharmaceuticals PLC during the first quarter valued at $208,000. Bank of Montreal Can raised its position in Jazz Pharmaceuticals PLC by 171.4% in the first quarter. Bank of Montreal Can now owns 45,770 shares of the specialty pharmaceutical company’s stock valued at $6,644,000 after buying an additional 28,904 shares during the last quarter. Finally, Gateway Investment Advisers LLC raised its position in Jazz Pharmaceuticals PLC by 13.0% in the first quarter. Gateway Investment Advisers LLC now owns 73,395 shares of the specialty pharmaceutical company’s stock valued at $10,652,000 after buying an additional 8,418 shares during the last quarter. 86.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.